Report : Asia Pacific Antibody Discovery Market Forecast to 2030 - Regional Analysis - by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, and Others), Nature (Human and Humanized, Chimeric, and Murine), Services (Phage Display, Hybridoma, Transgenic Animal, Single Cell, and Yeast Display), and End User (Pharmaceutical and Biotechnology Companies, Research Laboratories, and Others)
At 7.3% CAGR, Asia Pacific Antibody Discovery Market is Projected to be Worth US$ 11,58,681.86 Million by 2030, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific antibody discovery market was valued at US$ 6,58,965.05 million in 2022 and is expected to reach US$ 11,58,681.86 million by 2030, registering a CAGR of 7.3% from 2022 to 2030. Rising incidence of cancer and proliferation of biotechnology industry in developing regions are among the critical factors attributed to drive the Asia Pacific antibody discovery market growth.
As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the world. The GLOBOCAN further estimates that the cancer cases in India would reach ~2.08 million by 2040, representing a rise of 57.5% from 2020. Similarly, as per the World Health Organization (WHO) data published in February 2022, ~10 million people have died from cancer worldwide. By January 2030, the population of cancer survivors is estimated to reach 22.1 million, which can be primarily associated with the aging of the population. Lung, breast, colorectal, prostate, and breast are among the most commonly reported cancer types. The rising incidences of cancer have raised concerns worldwide. Below is the list of common cancer cases reported worldwide in 2020.
New Cancer Cases Worldwide, in 2020
Sr. No. | Cancer Type | Number of Cases (Million) |
1 | Stomach | 1.09 |
2 | Skin (non-melanoma) | 1.2 |
3 | Prostate | 1.41 |
4 | Colon and rectum | 1.93 |
5 | Lung | 2.21 |
6 | Breast | 2.26 |
Source: World Health Organization, February 2020
Cancer is now a lifestyle disease commonly seen among people with unhealthy eating habits and those who don’t engage much in physical activities. The frequent consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody–drug conjugates (ADCs) have also shown promising results in cancer treatment. Further, progress in modern biotechnology allows researchers and companies to provide well-designed novel antibodies, paving the way for successful treatments of various types of cancer. Thus, the burgeoning incidence of different types of cancer boosts the antibody discovery market growth.
On the contrary, high cost of production hampers the growth of Asia Pacific antibody discovery market.
Based on antibody type, the Asia Pacific antibody discovery market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held 83.8% market share in 2022, amassing US$ 552.16 billion. It is projected to garner US$ 992.92 billion by 2030 to register 7.6% CAGR during 2022–2030.
In terms of nature, the Asia Pacific antibody discovery market is segmented into human and humanized, chimeric, and murine. The human and humanized segment held 57.2% share of Asia Pacific antibody discovery market in 2022, amassing US$ 377.19 billion. It is anticipated to garner US$ 686.55 billion by 2030 to expand at 7.8% CAGR during 2022–2030.
By services, the Asia Pacific antibody discovery market is divided into phage display, hybridoma, transgenic animal, single cell, and yeast display. The phage display segment held 37.0% share of Asia Pacific antibody discovery market in 2022, amassing US$ 243.81 billion. It is projected to garner US$ 450.14 billion by 2030 to expand at 8.0% CAGR from 2022 to 2030.
Based on end user, the Asia Pacific antibody discovery market is categorized into pharmaceutical and biotechnology companies, research laboratories, and others. The pharmaceutical and biotechnology companies segment held 55.1% share of Asia Pacific antibody discovery market in 2022, amassing US$ 363.35 billion. It is predicted to garner US$ 665.94 billion by 2030 to expand at 7.9% CAGR between 2022 and 2030.
Based on country, the Asia Pacific antibody discovery market is categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.5% share of Asia Pacific antibody discovery market in 2022. It was assessed at US$ 200.98 billion in 2022 and is likely to hit US$ 364.52 billion by 2030, registering a CAGR of 7.7% during 2022-2030.
Key players operating in the Asia Pacific antibody discovery market are Charles River Laboratories International Inc, BioDuro LLC, Sartorius AG, Aragen Life Sciences Ltd, Twist Bioscience Corp, and Biocytogen Pharmaceuticals Beijing Co Ltd, among others.
- In January 2024, Biocytogen Pharmaceuticals Co Ltd launched a new sub-brand, RenBiologics, to represent the company’s antibody discovery business division. RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice, the company’s fully human antibody/TCR discovery platforms.
- In August 2023, Twist Bioscience Corp announced a drug discovery agreement with Ono Pharmaceutical Co Ltd to discover and develop novel antibodies for the treatment of autoimmune diseases.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com